Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease
Status:
Terminated
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Heart failure (HF) is an epidemic and is a major burden on the US healthcare system. The most
common cardiovascular endpoint is HF. Thus, novel interventions to prevent HF in chronic
kidney disease (CKD) are highly desirable. This study will assess: the variability in the
response to isosorbide mononitrate (ISMN) therapy; the degree of change in central
hemodynamics and cardiac endpoints through analysis of changes in left ventricle (LV) mass,
diffuse myocardial fibrosis, and myocardial systolic and diastolic function.